Pharmacokinetic and Pharmacodynamic Analysis of Ferulic Acidpuerarin-Astragaloside in Combination with Neuroprotective in Cerebral Ischemia/reperfusion Injury in Rats

Li-Jun Ge,Shou-Yan Fan,Jie-Hong Yang,Yi Wei,Zhen-Hong Zhu,Yi-Jia Lou,Ying Guo,Hai-Tong Wan,Yi-Qiang Xie
DOI: https://doi.org/10.1016/s1995-7645(14)60334-5
2015-01-01
Asian Pacific Journal of Tropical Medicine
Abstract:Objective: To investigate the effects of the active ingredients combined therapy on inflammatory factors interleukin 1 beta (IL-1 beta) and neuropeptide Y (NPY) based on pharmacodynamics in rats. Methods: The animal model was built by transient middle cerebral artery occlusion (MCAO). The method for evaluating the concentrations of the FA-Pr-Al components in rat plasma was established by using HPLC and the expression levels of IL-1 beta and NPY were determined by ELISA. A new mathematics method of the trend of percentage rate of change (PRC) was used to assess the correlation between pharmacokinetics (PK) and pharmacodynamics (PD). Results: FA-Pr-Al in combination reduced neurological deficits, decreased infarct volume and inhibited the expression levels of IL-1 beta and NPY (all P<0.05) compared with the model group. FA, Pr and Al all displayed two compartment open models in rats. Clockwise hysteresis loops were obtained by time-concentration-effect curves. IL-1 beta and NPY level changes in the plasma followed an opposite trend to the plasma concentration tendency after C-max was reached. Astragaloside's PRC value was significantly higher than those of FA and puerarin between 120 to 180 min. Conclusions: The pharmacokinetics of FA-Pr-Al in combination were closely related its pharmacodynamics in treating ischemia/reperfusion injury, and the components of FA-Pr-Al may have a synergistic pharmacological effect. Astragaloside may play a more pronounced role in regulating IL-1 beta and NPY levels compared with puerarin or FA.
What problem does this paper attempt to address?